Drug Target Review
NOVEMBER 1, 2023
2,8-10 However, the number of compounds with satisfying pharmacokinetic parameters (PKD) are limited, with most unable to cross the blood-brain barrier or go sufficiently deep into a malignant tumour. 2017 Mar 9;60(5):2006–17. Recently, our laboratory discovered a potent partial inhibition of ATX by cannabinoids in a nanomolar range.
Drug Target Review
JUNE 12, 2023
What are the preclinical characteristics of ISM6331, including its efficacy, safety profile, and drug metabolism and pharmacokinetics (DMPK) properties? Prior to founding Insilico, Alex worked in senior roles at ATI Technologies (a GPU company acquired by AMD in 2006), NeuroGNeuroinformatics, and the Biogerontology Research Foundation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JUNE 6, 2023
We are currently selecting our lead IL-18 variant on the basis of potency for the IL-18 receptor, optimal pharmacokinetic profile and in vivo efficacy for inhibiting tumour growth. American Association for Cancer Research; 2006 [cited 2023 Jun 6]. Ultimately, our goal is for this approach to yield an enhanced cancer fighting response.
The Pharma Data
APRIL 4, 2023
As part of the comprehensive submission package to the European Marketing Authorization, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing its approved adalimumab 50 mg/mL 2 with the 100 mg/mL (HCF). It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.
Drug Target Review
OCTOBER 4, 2023
7 These inhibitors have faced challenges such as dose-limiting toxicity and poor pharmacokinetics, but geldanamycin ADCs have demonstrated increased survival in mice. 12 , 2955–2960 (2006). 9 Others, like psymberin, have been used as ADC payloads, with a β-glucuronide linker to target CD-30-positive and CD-70-positive malignancies.
The Pharma Data
APRIL 7, 2021
The EC’s approval of the SC route of administration for TYSABRI is based on data from the DELIVER and REFINE studies, which showed comparability to the Q4W IV administration of 300mg TYSABRI in efficacy, pharmacokinetic and pharmacodynamic profiles.
New Drug Approvals
JANUARY 13, 2023
January 2006). “SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers” Journal of Cardiovascular Pharmacology. 36 (Database issue): D901-6. doi : 10.1093/nar/gkm958. PMC 2238889. PMID 18048412. PMID 9156352.
Expert insights. Personalized for you.
134 
Let's personalize your content